Protecting Intellectual Property in Engagements with CMOs

Publication
Article
BioPharm InternationalBioPharm International-06-15-2015
Volume 2015 eBook
Issue 1

Important IP contractual provisions should be included when working with CMOs.

 

Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.

 

Download

BioPharm International’s 2015 Outsourcing Resources eBook

.

 

 

 

 

 

Articles in this issue
BPsupp0615__QRM_200.jpg
QRM Tools for Contract Biomanufacturing
BPsupp0615_LangerFillFinish_200.jpg
Fill/Finish Trends
BPsupp0615_Feature_roundtable_200.jpg
Biopharma Advances Demand Specialized Expertise
BPsupp0615_IPLaw_200.jpg
Protecting Intellectual Property in Engagements with CMOs
BPsupp0615_Neostem_200.jpg
Taking a “Development-by-Design” Approach to Cell Therapies
Recent Videos
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Voyager Pauses IND Filing while Assessing Alternate Payloads for SOD1 ALS Gene Therapy Program

Feliza Mirasol
February 13th 2025
Article

The company plans to assess alternate payloads for its gene therapy program, which will shift its timeline.

Train moving fast from 2023 to 2025 in tunnel | Image Credit: ©xy – stock.adobe.com

Innovation Accelerates into the Future

Felicity Thomas
February 12th 2025
Article

Personalized medicine is a trend that continues to impact innovation and business decisions in the biopharma industry.

Black female scientist looking through microscope while working in laboratory. | Image Credit: ©Drazen - stock.adobe.com

The 10th Anniversary of the International Day of Women and Girls in Science

Susan Haigney
February 11th 2025
Article

Feb. 11, 2025 marks the 10th anniversary of the International Day of Women and Girls in Science.

Group of participants engaging in interactive business seminar, with one individual raising hand while seated and another person presenting in background with laptop | Image Credit: © Seventyfour - stock.adobe.com

Split Opinions on Training Strategies

Patrick Lavery
February 8th 2025
Article

Survey results show that being intellectually stimulated and getting assigned challenging projects are two key drivers of employee satisfaction, yet job training is lacking.

Medical capsule with DNA inside, 3d rendering. | © Vink Fan– Stock.Adobe.com – © Vink Fan – stock.adobe.com

Navigating a Growing Field of New Biotherapeutic Modalities

Feliza Mirasol
February 7th 2025
Article

Development of new modalities of biotherapeutic molecules will rely on manufacturing, regulatory, and collaborative support.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Grifols Teams Up with Startup, FcR Therapeutics, on Recombinant Therapies for Autoimmune Diseases

Feliza Mirasol
February 6th 2025
Article

Under this early stage R&D collaboration, the companies aim to engineer recombinant biologics for blocking Fc receptors, which play a key role in autoimmune diseases.

© 2025 MJH Life Sciences

All rights reserved.